Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/18/25 | $66,000,000 | Series B |
Canaan Partners Deerfield Management Company, L.P. DROIA Ventures Euclidean Capital Regeneron Ventures | undisclosed |
